ABCG2 and cancer: Herein, we shifted the experimental setting to human cancer cell lines and combined treatment of ABCG2 inhibitors and cytostatic drugs, displaying three synergistic combinations in MCF-7 Doxo, three in SW480, and two in HT29 cell lines.